Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) — Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at […]